Sexuality and Management of Benign Prostatic Hyperplasia with Alfuzosin: SAMBA Thailand

Journal of Sexual Medicine

Volumn 7, Issue 9, 2010, Pages 3115-3126

  Leungwattanakij, Somboon ^a   Watanachote, Damrongpun ^a   Noppakulsatit, Patra ^b   Petchpaibuol, T ^b   Choeypunt, Nopporn ^c   Tongbai, Thanasak ^d   Wanamkang, Teerawan ^d   Lojanapiwat, Bunnakij ^e   Permpongkosol, Sompol ^f   Tantiwong, Anupan ^g   Pripatnanont, Chusak ^h   Akarasakul, Danaipan ⁱ   Kongwiwatanakul, Somsak ^j   Chotikawanich, Ekarat ^k  

^a Bangkok Hospital Medical Center   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

^c PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^d Urology Section   (Thailand)

^e Faculty of Medicine Chiang Mai University   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h PRINCE OF SONGKLA UNIVERSITY   (Thailand)

ⁱ RAJAVITHI HOSPITAL   (Thailand)

^j CHONBURI HOSPITAL   (Thailand)

^k KHON KAEN UNIVERSITY   (Thailand)

more..

Author keywords

Alpha blocker; Benign prostatic hyperplasia; Ejaculation; Lower urinary tract symptoms; LUTS

Indexed keywords

ALFUZOSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; NITRIC ACID DERIVATIVE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ADULT; ARTICLE; BLOOD PRESSURE; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EVENING DOSAGE; HEART RATE; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; ISCHEMIC HEART DISEASE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL FUNCTION; SEXUAL HEALTH; SEXUALITY; SIDE EFFECT; THAILAND; TREATMENT DURATION; TREATMENT OUTCOME; URINE RETENTION;

EID: 77956293465     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01743.x     Document Type: Article

References (43)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474-9.
2. Oishi K, Boyle P, Barry JM. Epidemiology and natural history of benign prostatic hyperplasia. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), Paris July 2-5, 1997 1998, 25-59. Denis L, Griffiths K, Khoury S. ed, Plymouth, UK, Health Publications
3. Madersbacher S, Alivizatos G, Jorgen N, Carlos RS, Mark E. EAU 2004 Guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH Guidelines). Eur Urol 2004, 46:547-54.
4. Sak SC, Eardley I. What is the relationship between benign prostatic hyperplasia and sexual function? Sex Relat Ther 2004, 19:431-43.
5. Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis 2001, 4(1):S12-6. suppl
6. Daly MP. Quality of life in sexually active men with symptomatic benign prostatic hyperplasia. Effects of treatment. Clin Drug Invest 2005, 25:219-30.
7. Rosen RC, Riley A, Gorn W, Ian HO, Johm K. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822-30.
8. Holtgrewe HL. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 1998, 51(4A):1-7. suppl
9. Jardin A, Andersson KE. Caine M.a-blockers in the treatment of BPH. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), Paris July 2-5, 1997 1998, 599-32. Denis, Griffiths LKhoury KS. ed, Plymouth, UK, Health Publications, SCI
10. AUA Guidelines on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations. J Urol 2003, 170:530-47. AUA Practice Guidelines Committee
11. Vallancien G. Alpha-blockers in benign prostatic hyperplasia. Urology 1999, 54:773-5.
12. Lefevre-Borg F, O'Conner SE, Schoemaker H, Hicks PE, Leschaire J, Gautier E, Pierre F, Pimoule C, Manoury P, Langer SZ. Alfuzosin, a selective α1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 1993, 109:1282-989.
13. Martin D, Jammes D, Angel I. Effects of alfuzosin on urethral and blood pressures in conscious male rats. Life Sci 1995, 57:387-91.
14. Teillac P, Delauche-Cavallier MC, Attali P. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992, 70:58-64.
15. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH. Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1994, 157:169-76. suppl
16. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5 mg in subjects with benign prostatic hyperplasia. Eur Urol 1997, 31:190-8.
17. Lukacs B, Leplege A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin. Urology 1996, 48:731-40.
18. Lukacs B, Comet D, Doublet D, Grange JC, Gattegno B. Health related quality-of-life in benign prostatic hyperplasia patients treated for 2 years with alfuzosin. J Epidemiol Biostat 1997, 2:203-11.
19. Jeroen R, Rudolf H, Mark E, Neils H, Haim M, Elhilali Mostafa, Alcaraz Antonio, Vallancien Guy. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005, 95:603-8. for the ALF-ONE Study Group
20. McNeill SA, Hargreave TB, Claus GR, Roehrborn CG. Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study. Urology 2005, 65:83-90. Alfaur Study Group
21. Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol 2006, 175:624-8. for the ALF-ONE Study Group
22. Guy V, Mark E, Niels H, Jeroen AR. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003, 169:2257-61.
23. Raymond CR, John MF. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 2009, 104:979-83.
24. Raymond CR, Joseph C, Lance P, Stanley A, O'Leary M, Seftel AD. Male Sexual Health Questionnaire (MSHQ): Scale develeopment and psychometric validation. Urology 2004, 64:777-82.
25. Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between lower urinary tract symptoms (LUTS) and sexual function in benign prostatic hyperplasia: Impact of treatment of LUTS on sexual function. J Sex Med 2009, 6:2299-304.
26. Wong SY, Leung JC, Woo J. A prospective study on the association between lower urinary tract symptoms (LUTS) and erectile dysfunction: Results from a large study in elderly Chinese in Southern China. J Sex Med 2009, 6:2024-31.
27. Van Kerrebroeck P, Jardin A, van Cangh P, Laval KU. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-label extension study. Eur Urol 2002, 41:54-61.
28. Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res 2007, 480-5.
29. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Ecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009, 6:544-52.
30. Oger S, Behr-Roussel D, Gorny D, Charles Tremeaux J, Combes M, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008, 5:935-45.
31. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008, 5:2170-8.
32. Lukacs B. Assessment of male sexual function. Prostate Cancer Prostatic Dis 2001, 4:S7-11.
33. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007, 51:1717-23.
34. Oger S, Behr-Roussel D, Gorny D, Lebret T, Denoux Y, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2009, 57:699-707.
35. Man-Kay L, Lester AG, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: A survey of ageing men from five Asian countries. BJU Int 2005, 96:1339-54.
36. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associatied with benign prostatic hyperplasia. Eur Urol 2005, 47:824-37.
37. Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008, 15:915-8.
38. Kobayashi K, Masumori N, Hisasue S, Kato R, Hashimoto K, Itoh N, Tsukamoto T. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med 2008, 5:2185-90.
39. Vallancien G, Emberton M, Alcaraz A. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice. BJU Int 2008, 101:847-52.
40. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003, 44:637-49.
41. Zlotta AR, Schulman CC. BPH and sexuality. Eur Urol 1999, 36(1):107-12. suppl
42. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006, 176:1529-33.
43. Hellstrom WJ, Sikka SC. Effects of alfuzosin and tamsulosin on sperm parameters in healthy men: Results of a short-term, randomized, double-blind, placebo-controlled, crossover study. J Androl 2009, 30:469-74.